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New-onset diabetes after liver transplantation (NODALT) is a frequent complication with an unfavorable outcome. We previously demonstrated a crucial link between donor graft genetics and the risk of NODALT. We selected 15 matched pairs of NODALT and non-NODALT liver recipients using propensity score matching analysis. The donor liver tissues were tested for the expression of 10 microRNAs (miRNAs) regulating human hepatic glucose homeostasis. The biological functions of potential target genes were predicted using gene ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. Both miR-103 and miR-181a were significantly highly expressed in the NODALT group as compared to the non-NODALT group. The predicted target genes (e.g. Irs2, Pik3r1, Akt2, and Gsk3b) were involved in glucose import and the insulin signaling pathway. We also observed dysregulation of miRNAs (e.g. let-7, miR-26b, miR-145, and miR-183) in cultured human hepatocytes treated with tacrolimus or high glucose, the two independent risk factors of NODALT identified in this cohort. The hepatic miRNA profiles altered by tacrolimus or hyperglycemia were associated with insulin resistance and glucose homeostatic imbalance as revealed by enrichment analysis. The disease susceptibility miRNA expressive pattern could be imported directly from the donor and consolidated by the transplant factors.
Abbreviations: BMI, body mass index; CREB, cyclic adenosine monophosphate responsive element binding protein; GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and
Introduction
New-onset diabetes after liver transplantation (NODALT) is a frequent complication in liver recipients and is associated with an unfavorable clinical outcome (1, 2) . Some well-known risk factors in recipients have been identified, such as overweight, family history of diabetes mellitus, hepatitis C viral infection and immunosuppressive regimens (1, 2) . However, the underlying mechanism for the development of NODALT remains poorly understood.
In our recent review, we proposed that the liver graft itself could be the origin of NODALT (3) . The liver is a well-known metabolic center and plays a key role in the glucose metabolism and homeostasis in liver transplant recipients. An increased amount of evidence has emerged that both the phenotype and genotype of the graft are involved in the development of NODALT (4, 5) .
MicroRNA (miRNA) is a small, noncoding, single-stranded RNA that functions in RNA silencing and posttranscriptional regulation. It plays important roles in maintaining normal physiology and in disease processes. Compared to messenger RNA (mRNA), miRNA is well conserved among vast species and highly stable in tissues, which makes it a promising modality in disease diagnosis, prognosis and therapy. It has been revealed that graft miRNA profiles could identify the risk of hepatitis C virus recurrence after liver transplantation (6) . It is also known that miRNAs are involved in hepatic glucose metabolism. For instance, let-7 (7), miR-29a (8), miR-103/107 (9,10), miR-143/145 (11, 12) , miR-181a (13), miR-183 (14) , and miR-802 (15) impair hepatic insulin sensitivity, whereas miR-130a (16) and miR-26a (17) increase insulin signaling. In addition, miR-22-3p (18) and miR-26a (17) suppress gluconeogenesis. The dysregulation of hepatic miRNAs is closely associated with metabolic diseases. Therefore, in this study, we aimed to evaluate the impact of donor graft miRNAs on the development of NODALT. 
Patients and Methods

Patients
Data collection and definition
Patient demographics and clinical characteristics such as body mass index (BMI), primary liver disease, comorbidities, and biochemistry parameters (collected 24 h before transplantation) were obtained from the hospital's electronic medical records. The posttransplant blood glucose levels and TAC concentrations were monitored as closely as possible within the first 3 months after liver transplantation (4). NODALT was defined as a fasting blood glucose level of ≥7 mmol/L, a nonfasting blood glucose level of ≥11.1 mmol/L confirmed on at least two occasions or a need for antidiabetic drugs persisting beyond the first month after transplantation (4). Early hyperglycemia was defined as a fasting blood glucose level of ≥7.0 mmol/L confirmed on at least two occasions within the first posttransplant month (<30 days) (19) . Extended-criteria donors include those over the age of 50, or with steatosis > 30%, or cold ischemia time > 12 h (20) . 
Cell culture
Western blot analysis
Western blot analysis was performed as described previously. 
Statistical analysis
Quantitative variables were described as the mean AE standard deviation (SD), while categorical variables were presented as values (percentages). Quantitative variables were compared using an independent-samples ttest or the Mann-Whitney test, and categorical variables were compared using Pearson's v 2 test (Fisher's exact test). Cumulative survival was compared using Kaplan-Meier analysis with the log-rank method. The risk factors were evaluated by logistic regression analysis. Patient selection was performed by propensity score matching (22) . Pearson's productmoment correlation coefficient was used to evaluate the correlation. SPSS version 13.0 (SPSS Inc., Chicago, IL) was used to complete the analyses. A p-value of <0.05 was considered statistically significant.
Results
Donor graft miRNAs are expressed differently in NODALT and non-NODALT patients Out of 213 liver recipients, 61 (28.2%) developed NODALT, with a median duration of 38 days (range: 30-423 days) postoperatively. As determined by logistic analysis, early hyperglycemia and high blood TAC concentration were two independent risk factors of NODALT, increasing disease risk by 1.7-fold and 2.1-fold, respectively (Table 1) .
Matched by the aforementioned two risk factors as well as age and gender, 43 pairs of NODALT and non-NODALT patients were initially selected. After eliminating recipients with extended-criteria donors, 15 matched NODALT and non-NODALT cases were chosen ( Table 2 ). Compared to the non-NODALT group, the NODALT patients had significantly higher miR-103 (p = 0.013, fold change = 2.6) and miR-181a (p = 0.002, fold change = 3.5) expression ( Figure 1A ). The expression of the other eight miRNAs did not differ significantly between the two groups ( Figure S1 ). Furthermore, donor graft miR-103 and miR-181a levels were positively correlated with fasting blood glucose levels following liver transplantation (p < 0.05) ( Figure 1B ). According to GO and KEGG pathway analyses, the predicted target genes of miR-103 and miR-181a were involved in glucose import and the insulin signaling pathway-e.g. Irs1, Irs2, Pik3r1, Akt2, Gsk3b, Gys2, G6pc2, Hnf1a, Tcf7l2, and Foxo1 (Table S2) .
TAC and hyperglycemia induce dysregulation of hepatic miRNAs TAC has been considered a predominant contributor of new-onset diabetes after solid organ transplantation. To evaluate the impact of TAC on hepatic miRNA profiles, we treated HepG2 cells with 0, 5 and 20 ng/mL of TAC for 24 h and compared the expression of miRNAs using microarrays. We observed 124 and 60 different expressed miRNAs between the low-dose TAC group and the control group, as well as between the high-dose TAC group and the control group, respectively (Table S3) . Twenty-seven miRNAs were significantly upregulated by both low-and high-dose TAC, mostly in a dose-related manner (Table 3) . Their predicted target genes underwent GO and KEGG pathway analyses ( Figure S2 ). We observed that TAC inhibited the calcium signaling pathway-e.g. Calm1, Camk2b, and Camk2g. Furthermore, two well-described molecular targets of TAC in regulating insulin secretionthe cyclic adenosine monophosphate (cAMP) responsive element binding protein (CREB) transcriptional coactivator and the nuclear factor of activated T cells (NFAT)-were predicted to be the targets of miR-4492 and miR-320e, respectively. The main glucose metabolism-and insulin signaling-associated pathways are presented in Table 4 .
Out of the 27 miRNAs, let-7 (7) and miR-183 (14) were reported to impair hepatic insulin sensitivity, and miR-26b (23) was revealed to promote lipid synthesis and accumulation. We also noted that Tcf7l2 and Foxo1, which are key molecules in the activation of gluconeogenesis, are targeted by miR-183. In addition, Irs2/Akt2 and Gsk3b, which are associated with insulin signal transduction, are targeted by let-7 and miR-26b. We then verified the results in both HepG2 and HUH7 cells using real-time PCR that TAC increased the expressions of let-7a, miR26b and miR-183 in a dose-related manner (Figure 2A ). NODALT, new-onset diabetes after liver transplantation; OR, odds ratio; CI, confidence interval; TAC, tacrolimus. We also found that prolonged incubation time resulted in elevated expressions of let-7a, miR-26b and miR-183 only after a high concentration of TAC treatment (20 ng/mL) but not in a low concentration (5 ng/mL) (Figures 2BandC ). Furthermore, we tested the mRNA levels and protein contents of the potential targets and found that they were decreased by TAC ( Figure 2D ).
Early hyperglycemia was the other independent risk factor of NODALT besides TAC. To assess the effect of high glucose on hepatic miRNA levels, we treated HepG2 and HUH7 cells with 5.5, 10, and 30 mM of glucose for 24 h and tested for the expression of miRNAs. The expressions of miR-145 and miR-183 were increased after high glucose exposure in both cell lines (Figure 3) , whereas the other eight miRNAs were not increased ( Figure S3 ). Furthermore, we found that the elevation of miR-145 and miR-183 was time related in a 10-mM glucose medium (Figure 3) . The predicted target genes are key regulators involved in gluconeogenesis (e.g. Tcf7l2, Foxo1), glycogen synthesis (e.g. Gyg2, Gys1) and insulin signaling (e.g. Irs1, Irs2, Akt1, Akt2, Akt3).
Discussion
We have previously demonstrated that donor grafts carry disease susceptibility genes to recipients and contribute to the development of metabolic disorders (4, 24) . This study, from the view of miRNA, further confirmed our previous findings and demonstrated that donor grafts with certain miRNA profiles had a greater risk of developing NODALT. We found markedly higher hepatic miR-103 and miR-181a expression in liver recipients with NODALT as compared to those without NODALT in a propensitymatched cohort. Elevated miR-103 and miR-181a levels in the donor grafts correlated with increased blood glucose levels following liver transplantation. The possible underlying mechanism is that the two miRNAs target several key genes involved in insulin signal transduction and glucose homeostasis, as revealed by the enrichment analysis. Among these predicted targets, some have been verified by previous studies. Trajkovski et al (10) have demonstrated that miR-103 directly targets caveolin-1, thereby diminishing the number of insulin receptors and reducing downstream insulin signaling in both human and rodent models. Zhou et al (13) have shown that miR-181a directly targets sirtuin-1 and induces hepatic insulin resistance in human hepatocytes and transgenic mouse models. Therefore, we believe that the addition of miR-103 and miR-181a to the donor graft impairs hepatic insulin sensitivity, which could be the "first hit" in the development of NODALT.
Furthermore, we propose that hyperglycemia and TACthe two identified independent risk factors of NODALT in this study-act as a "second hit" in the development of NODALT. Immunosuppressive drugs have long been regarded as the major contributor to the development of diabetes in almost all types of solid organ transplantation. Since the implementation of the steroid-free protocol among organ transplantation recipients, calcineurin inhibitors, mainly TAC, have been regarded as one of the primary diabetogenic agents (19, 25) . Clinical studies-as well as our current work-have shown the significance of TAC in the development of NODALT (4, 19, 25, 26) . However, the underlying mechanism has not yet been fully elucidated. Previous experimental studies have demonstrated that TAC reduces insulin secretion in pancreatic b cells (27) and may also induce insulin resistance (28) . We provide evidence that the liver is another target organ of TAC. Hepatic glucose homeostasis could be altered by TAC via regulating miRNA expression. As revealed by the enrichment analyses, TAC could potentially upregulate the expression of 27 miRNAs and affect the glucose metabolic process and insulin signaling transduction. We further proved that TAC can induce hepatic insulin resistance via upregulation of let-7 and miR-26b, which target the IRS2/PI3K/AKT pathway. TAC also attenuated gluconeogenesis by upregulation of miR-183, which targets TCF7L2 and FoxO1. Only a high concentration of TAC could induce the time-dependent elevation of certain miRNA profiles that are involved in hepatic glucose metabolism. This may explain the higher risk of developing NODALT in patients with a high concentration of TAC.
According to a recent national report, hyperglycemia in the immediate posttransplant period is considered a major predictor of NODALT (19) . In kidney transplant recipients, immediate posttransplant insulin therapy, leading to better blood glucose control, was found to reduce the risk of developing new-onset diabetes (29) . One possible explanation is glucose's direct toxicity in pancreatic b cells (30); another is hyperglycemia-induced peripheral insulin resistance (31) . In vitro experiments usually require high glucose exposure to establish insulin-resistant models. In human and rodent hepatocytes, high glucose treatment significantly inhibits AKT phosphorylation and IRS-1 expression and subsequently reduces glucose uptake (31, 32) . A recent gene network analysis in human liver cancer cells showed that high glucose concentration regulates the transcription of genes involved in several signaling pathways, including glycolysis, regulators of reactive oxygen species production (e.g. glucose oxidase, cyclooxygenase 2, adenosine monophosphate kinase [AMPK]) and second-messenger signaling pathways (e.g. PI3K/AKT) (33) . In this study, we showed that high glucose treatment modulated the expression of hepatic miRNAs, which presented as an insulin-resistant pattern.
In high-glucose stressed human hepatocytes, the expressions of miR-29a and miR-145 were significantly increased in a dose-and time-dependent manner. The predicted target genes were involved in hepatic glucose homeostasis and insulin signal transduction. Therefore, hyperglycemia may induce the alteration of hepatic miRNAs and subsequently lead to hepatic insulin resistance and glucose homeostatic imbalance.
We acknowledge that this study has some limitations. First, this was a single-center study with a small sample size. In order to control confounding factors and better elucidate the effect of the genetic profile, only a limited number of cases were selected for the study. Therefore, the results need to be validated in large cohorts, preferably including other ethnic populations. Second, although the diagnostic criteria of brain death were defined by the Chinese Ministry of Health in 2003, brain death in organ donation has not been widely accepted by the general public in China because of the culture barrier. Donation after circulatory death provides the predominant source of organs for transplantation during the study period. We excluded extended-criteria donors such as those with aged livers (34) , fatty livers (35) , and grafts with prolonged ischemia time (36) , which could potentially bring diabetes susceptibility genes to the recipients. However, donation after circulatory death of the graft itself might increase the risk of developing NODALT due to warm ischemia (5) . Therefore, the results also need to be verified among patients receiving liver grafts from donors after brain death.
In summary, donor graft miRNAs targeting multiple genes involved in hepatic glucose metabolism and insulin signaling are associated with the development of NODALT. The disease susceptibility miRNA expressive pattern could be imported directly from the donor and could be greatly consolidated and augmented by transplant factors such as early hyperglycemia and immunosuppressive drugs. The "two-hit" mechanism indicates that miRNA-targeted therapy in donor grafts may be a novel and promising strategy for the prophylaxis and treatment of NODALT and other posttransplant complications. 
Supporting Information
Additional Supporting Information may be found in the online version of this article. Table S1 : The polymerase chain reaction (PCR) primers. Table S2 : The glucose metabolism-associated gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses of potential target genes of miR-103 and miR-181a. Table S3 : The significant dysregulated microRNAs by tacrolimus. Table S4 : The glucose metabolism-associated gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses of potential target genes of miR-29a and miR-145. Figure S1 : The expressions of miR-22, miR-26a, miR29a, miR-107, miR-130a, miR-145, miR-183, and miR-802 did not differ significantly between patients with and without new-onset diabetes after liver transplantation (NODALT). Figure S2 : Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses for the target genes of the 27 miRNAs significantly upregulated by both low-and high-dose tacrolimus. Top 50 pathways with p-value <0.05 and false discovery rate (FDR) value <0.05 are shown. Figure S3 : The expressions of miR-22, miR-26a, miR-103, miR-107, miR-130a, and miR-181a did not differ significantly after high glucose exposure for 24 h in both cell lines (HepG2 and HUH7). The expression of miR-802 was undetectable. *p < 0.05.
